AR056269A1 - DERIVATIVES OF THIOAMIDS, ISOMERS OF THE SAME, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, AS THE VANYLOID RECEIVING ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Google Patents

DERIVATIVES OF THIOAMIDS, ISOMERS OF THE SAME, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, AS THE VANYLOID RECEIVING ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Info

Publication number
AR056269A1
AR056269A1 ARP060100648A ARP060100648A AR056269A1 AR 056269 A1 AR056269 A1 AR 056269A1 AR P060100648 A ARP060100648 A AR P060100648A AR P060100648 A ARP060100648 A AR P060100648A AR 056269 A1 AR056269 A1 AR 056269A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
alkoxy
disease
haloc1
Prior art date
Application number
ARP060100648A
Other languages
Spanish (es)
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of AR056269A1 publication Critical patent/AR056269A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

Este presente se refiere a los compuestos novedosos, isomeros de los mismos sales farmacéuticamente aceptables de los mismos como al antagonista del receptor vaniloide (receptor vaniloide 1; VR1; TRPV1); y a una composicion farmacéutica que contiene los mismos. La presente proporciona una composicion farmacéutica para prevenir o tratar una enfermedad tal como la dolencia, migrana, artralgia, neuralgia, neuropatías, danos en los nervios, enfermedad de la piel, hipersensibilidad de la vejiga urinaria, síndrome del intestino irritable, urgencia fecal, enfermedad de Crohn, un enfermedad respiratoria, irritacion de la piel, ojos o membranas mucosa, ulcera estomago-duodenal, enfermedades inflamatorias, enfermedad del oído y enfermedad cardíaca. Reivindicacion 1: Un compuesto de formula (1), un isomero de los mismos, o una sal farmacéuticamente aceptable de los mismos; en el que: X representa CHR13, en el que R13 representa hidrogeno, halogeno, o alquilo C1-5; Y representa CHR14, CHR14-CHR15, CR14=CR15, o una formula (2) o (3), en el que R14 y R15 son independientemente hidrogeno, alquilo C1-5, halogeno, o fenilo; R1 y R2 representan independientemente hidrogeno, -SO2R16, -SOR16, alquilo C1-5, alcoxi C1-5, halo-alquiloC1-5, alquenilo C2-5, alcoxicarbonilo C1-5, alquiltio C1-5, fenilo, o fenilo-alquiloC1-3, en el que, cada fenilo puede ser no sustituido o sustituido con uno o más sustituyentes seleccionados de carboxi, alquilo C1-5, halogeno, nitro, alquenilo C2-5, alcoxi C1-5, halo-alquiloC1-5, alquilcarbonilo C1-5, alquiltio C1-5, alquilsulfonilo C1-5, y alcoxicarbonilo C1-5, y R16 representa hidrogeno, amino, alquilo C1-5, alquenilo C2-5, alcoxi C1-5, halo-alquiloC1-5, trifluormetilo, fenilo, o fenilo-alquiloC1-3; R3 representa hidrogeno, hidroxi, alquilo C1-5, halo-alquiloC1-5, COOBu-t, MePhSO2-, fenilo, o fenilo-alquiloCl-3, en el que cada fenilo puede ser no sustituido o sustituido con uno o más sustituyentes seleccionados del carboxi, alquilo C1-5, halogeno, nitro, alquenilo C2-5, alcoxi C1-5, halo-alquiloC1-5, alquilcarbonilo C1-5, alquiltio C1-5, alquilsulfonilo C1-5, y alcoxicarbonilo C1-5; R4, R5, R6, y R7 independientemente representan hidrogeno, carboxi, alquilo C1- 5, halogeno, nitro, ciano, alquenilo C2-5, alquinilo C2-5, cicloalquilo C3-6, alcoxi C1-5, halo-alquiloC1-5, halo-alcoxiC1-5, alquilcarbonilo C1-5, alquilcarbonilamino C1-5, alquilsulfonilamino C1-5, fenilosulfonilamino, alquiltio C1-5, alquilsulfonilo C1-5, o alcoxicarbonilo C1-5; y R8, R9, R10, R11, y R12 independientemente representan hidrogeno, carboxi, alquilo C1-5, nitro, alquenilo C2-5, alcoxi C1-5, alquinilo C2-5, halo-alquiloC1-5, alquiltio C1-5, alquilsulfonilo C1-5, alquilcarbonilo C1-5, alcoxicarbonilo C1-5, o halogeno.This present refers to novel compounds, isomers of the same pharmaceutically acceptable salts thereof as to the vanyloid receptor antagonist (vanyloid receptor 1; VR1; TRPV1); and to a pharmaceutical composition that contains them. This provides a pharmaceutical composition to prevent or treat a disease such as ailment, migraine, arthralgia, neuralgia, neuropathies, nerve damage, skin disease, urinary bladder hypersensitivity, irritable bowel syndrome, fecal urgency, disease Crohn's disease, a respiratory disease, irritation of the skin, eyes or mucous membranes, stomach-duodenal ulcer, inflammatory diseases, ear disease and heart disease. Claim 1: A compound of formula (1), an isomer thereof, or a pharmaceutically acceptable salt thereof; wherein: X represents CHR13, in which R13 represents hydrogen, halogen, or C1-5 alkyl; Y represents CHR14, CHR14-CHR15, CR14 = CR15, or a formula (2) or (3), in which R14 and R15 are independently hydrogen, C1-5 alkyl, halogen, or phenyl; R1 and R2 independently represent hydrogen, -SO2R16, -SOR16, C1-5 alkyl, C1-5 alkoxy, C1-5 halo-alkyl, C2-5 alkenyl, C1-5 alkoxycarbonyl, C1-5 alkylthio, phenyl, or phenyl-C1 alkyl -3, wherein, each phenyl may be unsubstituted or substituted with one or more substituents selected from carboxy, C1-5 alkyl, halogen, nitro, C2-5 alkenyl, C1-5 alkoxy, haloC1-5 alkyl, alkylcarbonyl C1-5, C1-5 alkylthio, C1-5 alkylsulfonyl, and C1-5 alkoxycarbonyl, and R16 represents hydrogen, amino, C1-5 alkyl, C2-5 alkenyl, C1-5 alkoxy, haloC1-5 alkyl, trifluoromethyl, phenyl, or phenylC 1-3 alkyl; R3 represents hydrogen, hydroxy, C1-5 alkyl, haloC1-5 alkyl, COOBu-t, MePhSO2-, phenyl, or phenyl-C1-alkyl, in which each phenyl can be unsubstituted or substituted with one or more substituents selected of the carboxy, C1-5 alkyl, halogen, nitro, C2-5 alkenyl, C1-5 alkoxy, C1-5 haloalkyl, C1-5 alkylcarbonyl, C1-5 alkylthio, C1-5 alkylsulfonyl, and C1-5 alkoxycarbonyl; R4, R5, R6, and R7 independently represent hydrogen, carboxy, C1-5 alkyl, halogen, nitro, cyano, C2-5 alkenyl, C2-5 alkynyl, C3-6 cycloalkyl, C1-5 alkoxy, haloC1-5 alkyl , haloC1-5 alkoxy, C1-5 alkylcarbonyl, C1-5 alkylcarbonylamino, C1-5 alkylsulfonylamino, C1-5 alkylthio, C1-5 alkylsulfonyl, or C1-5 alkoxycarbonyl; and R8, R9, R10, R11, and R12 independently represent hydrogen, carboxy, C1-5 alkyl, nitro, C2-5 alkenyl, C1-5 alkoxy, C2-5 alkynyl, haloC1-5 alkyl, C1-5 alkylthio, C1-5 alkylsulfonyl, C1-5 alkylcarbonyl, C1-5 alkoxycarbonyl, or halogen.

ARP060100648A 2005-03-16 2006-02-22 DERIVATIVES OF THIOAMIDS, ISOMERS OF THE SAME, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, AS THE VANYLOID RECEIVING ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AR056269A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050021896 2005-03-16
US66234505P 2005-03-17 2005-03-17

Publications (1)

Publication Number Publication Date
AR056269A1 true AR056269A1 (en) 2007-10-03

Family

ID=36991887

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100648A AR056269A1 (en) 2005-03-16 2006-02-22 DERIVATIVES OF THIOAMIDS, ISOMERS OF THE SAME, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, AS THE VANYLOID RECEIVING ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Country Status (2)

Country Link
AR (1) AR056269A1 (en)
WO (1) WO2006098554A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007004157A0 (en) 2005-03-17 2007-10-31 Pfizer N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
MX2009000925A (en) 2006-07-27 2009-02-05 Amorepacific Corp Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same.
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CN102137851B (en) 2008-07-02 2014-08-27 株式会社爱茉莉太平洋 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
US9770454B2 (en) 2013-07-14 2017-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763824B2 (en) * 1999-02-22 2003-07-31 Medifron Dbt Co., Ltd. Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
RU2003130221A (en) * 2001-03-26 2005-04-10 Новартис АГ (CH) CONDENSED PYRIDINE DERIVATIVES INTENDED FOR USE AS AN ANAGONISTS OF A VANILLOID RECEPTOR IN TREATMENT OF PAIN
MY138086A (en) * 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
KR100707123B1 (en) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 4-methylsulfonylaminophenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical composition containing the same
KR20050039573A (en) * 2003-10-23 2005-04-29 주식회사 태평양 Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability

Also Published As

Publication number Publication date
WO2006098554A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
AR056943A1 (en) DERIVATIVES OF AMIDAS, ISOMERS OF THE SAME OR THE PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME AS THE ANTAGONIST OF THE VANILOID RECEIVER AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AR063211A1 (en) DERIVATIVES OF 3- (PIRIDIN-3-IL) ACRILAMIDE AND 3- (PIRIDIN-3-IL) PROPIONAMIDE, A METHOD FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF ASSOCIATED DISEASES WITH THE VANILOID RECEIVER.
PE20091099A1 (en) AMINOBENZAMIDE DERIVATIVES AS USEFUL AGENTS TO CONTROL ANIMAL PARASITES
CR9022A (en) NEW SULFONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
NO20060981L (en) Pyridazine derivatives and their use as therapeutic agents
PE20091694A1 (en) 6-HETEROARIL-IMIDAZO [1,2-a] PYRIDINES POLYSUSTITUTED DERIVATIVES AS MODULATORS OF NOT RECEPTORS AND THEIR PREPARATION
BRPI0515482A (en) heterocyclic derivatives and their uses as therapeutic agents
CL2008002542A1 (en) Imidazolyl pyridine derived compounds linked to a heterocycle via a vinyl, modulators of amyloid-beta activity; pharmaceutical composition comprising said compounds; and its use for the treatment of diseases such as Alzheimer's, dementia, Down syndrome or amyloidosis.
PE20070790A1 (en) 2-AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF HISTAMINE H-4 RECEPTOR ACTIVITY
PA8632701A1 (en) THERAPEUTIC COMPOUNDS
PE20060691A1 (en) SERINAMIDES REPLACED BY BENZOYL
AR054799A1 (en) OXINDOL DERIVATIVES
NO20091553L (en) Phenyl derivatives and their use as immunomodulators
ECSP105253A (en) DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS INHIBITORS OF PI3 CINASA
CL2012000001A1 (en) Heteroaryl-pyrazolopyrimidine-carboxamide derivative compounds, jak inhibitors; pharmaceutical composition comprising them; Useful for the treatment of rheumatoid arthritis, Chron's disease, dermatitis, psoriasis, among others.
AR052938A1 (en) N-SULFONYLAMINOFENILETIL-2-PHENOXYACETAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY RECEIVER VR1
DK1697371T3 (en) Azabicyclic heterocyclic compounds as cannabinoid receptor modulators
AR069490A1 (en) GLUCOCORTICOID RECEPTORS AGONISTS
ECSP077323A (en) NEW DERIVATIVES OF SULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
AR066972A1 (en) AZAPEPTIDIC DERIVATIVES
PA8627001A1 (en) COMPOUNDS FOR THE TREATMENT OF DISEASES
PE20060957A1 (en) PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
PE20110384A1 (en) DERIVATIVES OF ALKYLTIAZOLES CARBAMATES AND THEIR PREPARATION
UY29802A1 (en) ANALOGS OF PHENYLETHYLAMINE AND ITS USE IN THE TREATMENT OF GLAUCOMA
AR074353A1 (en) NAFTALEN-2-IL-ACETIC ACIDS SUBSTITUTED, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF THE SAME IN THE TREATMENT OF ALLERGIC DISEASES, SUCH AS RHINITIS, ASTHMA AND ATOPIC DERMATITITIS.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal